Last reviewed · How we verify
Acalabrutinib combination with Rituximab
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.
At a glance
| Generic name | Acalabrutinib combination with Rituximab |
|---|---|
| Also known as | Maintenance Phase |
| Sponsor | AstraZeneca |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex. Inhibition of BTK has been shown to be effective in treating certain types of non-Hodgkin lymphoma.
Approved indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Nausea
Key clinical trials
- A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain (PHASE2)
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (PHASE2)
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (PHASE3)
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL (PHASE3)
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (PHASE1, PHASE2)
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (PHASE1, PHASE2)
- A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL (PHASE1)
- A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib combination with Rituximab CI brief — competitive landscape report
- Acalabrutinib combination with Rituximab updates RSS · CI watch RSS
- AstraZeneca portfolio CI